A Prospective, Single-arm, Non-randomized Controlled Trial to Test the Effectiveness, Safety and Performance of a Novel Dental Obturation Material
A Prospective, Single-arm, Non-randomized Controlled Trial to Test the Effectiveness, Safety and Performance of a Novel Dental Obturation Material
The goal of this study is prospective, single-arm, non-randomized controlled trial to test the effectiveness, safety and performance of a novel dental obturation material. The main question sit answers is
The participants requiring root canal treatment will be treated with obturated using Endofill material and post-treatment follow-up vistis will be conducted for 1 year. This is a single-arm study with no comparison groups.
Study Title:
"A prospective, single-arm, non-randomized controlled trial to test the effectiveness, safety and performance of a novel dental obturation material."
Protocol Version and Date: Version 1.0 25 May 2023
Device Risk Category: Risk category: Class IIa, Rule 8 - medium risk device (according to EU MDR).
Background and Rationale:
Endofill (EF) is a low-viscosity, injectable, hydrophilic, light- curable endodontic sealer. It is an easy-to-use, single- material root canal obturation solution that circumvents the disadvantages of existing products, thus improving ease of handling and treatment time while maintaining the clinical outcome of root canal treatments at the level of state-of-the- art treatment methods.
Endofill is used after a conventional access cavity preparation, glide path preparation, determination of the working length, cleaning/shaping of a root canal with a suitable device and irrigating/disinfecting the canal with an irrigant solution.
Endofill has undergone pre-clinical testing and is a safe product. The benefits and risks of this investigational device shall be elaborated in the protocol.
Primary objectives:
To test the effectiveness of the Endofill device for root canal obturation up to 12-month follow-up period.
To test the performance of the Endofill device evaluated with periapical radiographs immediately on completion of procedure.
Secondary objectives:
To test the safety and effectiveness, of the Endofill device by evaluating the incidence of re-treatment cases up to a 12-month follow-up period.
Primary endpoints Primary effectiveness endpoint: To measure overall healing, through rate of reduction in apical periodontitis, from baseline up to 12 months post-procedure by measuring periapical radiolucency size.
Success is measured by the PAI (periapical index) scores which will be recorded at 3m, 6m and 12 months. Success is defined as either a fully healed lesion (i.e., with no periapical radiolucency visible on the radiograph at 12 month follow up) or a healing lesion (i.e., the periapical radiolucency has decreased in size at 12 month follow up compared to pre-procedure radiographic lesion size); with no clinical symptoms such as pain or swelling.
Performance endpoint:
To measure the successful and complete obturation of root canal measured by examining the periapical radiograph taken immediately after obturation.
Secondary endpoints:
Safety endpoint: To measure freedom from postoperative pain from completion of procedure up to 1 months of follow-up (FU) period (24 hours, 48 hours, 72 hours, 7 days, and 1 month). Pain is measured by VAS assessment.
Secondary effectiveness endpoint:
Successful healing of periapical lesion up to 12 months post-procedure. Long-term effectiveness success shall be defined as a continued reduction or complete absence of periapical lesion radiolucency at 12m follow up since procedure with no clinical symptoms (i.e no discomfort in treated tooth and no percussive pain during examination)
Device failure shall be defined as root canal re-treatment or extraction requirement due to the treatment itself as the cause of failure, up to 12m post procedure along with persistence of clinical symptoms.
The study involves a safety check at 3 months' time point post-procedure. This check will be performed on the first 10 subjects to assess the safety, effectiveness, and performance of the evaluated device.
A total of 63 subjects aged 18 years and above shall be included in this study. Study Procedure
The planned enrollment period is 6-9 months. The total expected duration of the clinical investigation is 2 - 2.5 years.
Statistical Considerations:
Full details of the analyses will be discussed in a separate statistical analysis plan (SAP). Briefly, the following endpoints will be analyzed:
Primary endpoints are
The secondary endpoints are
Questionnaire about the quality and usability of the device.
· Summary statistics of results will be reported.
Sample Size In order to be able to establish non-inferiority within a margin of 0.2 of the target rates of 0.85, a two-sided, 95% confidence interval for the healing rate must lie above 0.85 - 0.2 = 0.65. Assuming a pessimistic scenario where the true underlying healing rate of the Endofill device is 0.02 lower than the target rate of 0.85 (i.e., 0.83), data from 56 participants are needed. This yields a power of 80% for the study. Assuming a 10% drop out rate at 12 months, the required sample size is 63.
Inclusion Criteria:
• Patients aged 18-75 years with ASA (American Society of Anesthesiologists) classification 1 and 2.
ASA 1: A normal healthy patient. Example: Fit, non-obese BMI (Body Mass Index) under 30, a non-smoking patient with good exercise tolerance.
ASA 2: A patient with mild systemic disease. Example: Patient with no functional limitations and a well-controlled disease (e.g., treated hypertension, obesity with BMI under 35, frequent social drinker, or cigarette smoker).
Exclusion Criteria:
anupama.tripathi@odne.co+4144 589 68 03